Literature DB >> 19857112

Characterization of the epitope region of F1-2 and F1-5, two monoclonal antibodies to Botulinum neurotoxin type A.

Miles C Scotcher1, Eric A Johnson, Larry H Stanker.   

Abstract

F1-2 and F1-5 are mouse IgG1 monoclonal antibodies that bind the heavy chain of Botulinum neurotoxin serotype A (BoNT/A). To characterize the epitopes of F1-2 and F1-5, three complementary experimental approaches were selected. First, recombinant peptide fragments of BoNT/A heavy-chain were used in Western blots to identify the epitope regions. Second, a peptide phage display library was used to identify specific amino acids bound by F1-2 and F1-5, and these amino acids were mapped onto the three-dimensional structure of BoNT/A. Third, selected amino acids were mutated to alanine and the effects of the mutations on F1-2 and F1-5 binding were evaluated. Data from recombinant peptide fragment binding experiments suggested that the epitopes for antibodies F1-2 and F1-5 are located between amino acids R564 and S793 on the toxin heavy chain. Furthermore, elimination of amino acids from the amino terminus (R564-K595), or from the carboxyl terminus (N759-S793) of this fragment abolished binding of both F1-2 and F1-5, suggesting a conformational epitope for these antibodies. Peptide sequences deduced from antibody binding to the peptide phage display library suggested that tyrosine residues located at positions 748, 750, and 753 might form a significant part of the F1-2 and F1-5 epitope motif. Mutation of Y750 or Y753 to alanine significantly reduced binding of either antibody, while mutation of Y748 to alanine had no effect on antibody binding. The nucleotide and deduced amino acid sequences of the variable regions of the heavy chains of F1-2 and F1-5 are reported. The complementarity determining regions (CDRs) of the heavy chains were found to be 78% identical. It is possible that F1-2 and F1-5 bind the same epitope via the common amino acids within their CDRs.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19857112     DOI: 10.1089/hyb.2009.0022

Source DB:  PubMed          Journal:  Hybridoma (Larchmt)        ISSN: 1554-0014


  7 in total

1.  Epitope characterization of sero-specific monoclonal antibody to Clostridium botulinum neurotoxin type A.

Authors:  Cindi R Corbett; Erin Ballegeer; Kelly A Weedmark; M D Elias; Fetweh H Al-Saleem; Denise M Ancharski; Lance L Simpson; Jody D Berry
Journal:  Hybridoma (Larchmt)       Date:  2011-12

Review 2.  Immunity to ricin: fundamental insights into toxin-antibody interactions.

Authors:  Joanne M O'Hara; Anastasiya Yermakova; Nicholas J Mantis
Journal:  Curr Top Microbiol Immunol       Date:  2012       Impact factor: 4.291

3.  Novel epitopes identified by anti-PrP monoclonal antibodies produced following immunization of Prnp0/0 Balb/cJ mice with purified scrapie prions.

Authors:  Larry H Stanker; Miles C Scotcher; Alice Lin; Jeffery McGarvey; Stanley B Prusiner; Robert Hnasko
Journal:  Hybridoma (Larchmt)       Date:  2012-10

4.  Detection of botulinum neurotoxin serotype B at sub mouse LD(50) levels by a sandwich immunoassay and its application to toxin detection in milk.

Authors:  Miles C Scotcher; Luisa W Cheng; Larry H Stanker
Journal:  PLoS One       Date:  2010-06-10       Impact factor: 3.240

5.  Detection of botulinum neurotoxin serotypes A and B using a chemiluminescent versus electrochemiluminescent immunoassay in food and serum.

Authors:  Luisa W Cheng; Larry H Stanker
Journal:  J Agric Food Chem       Date:  2013-01-10       Impact factor: 5.279

6.  Development and Characterization of Monoclonal Antibodies to Botulinum Neurotoxin Type E.

Authors:  Candace S Bever; Miles Scotcher; Luisa W Cheng; Robert M Hnasko; Larry H Stanker
Journal:  Toxins (Basel)       Date:  2019-07-13       Impact factor: 4.546

7.  Rapid Microfluidic Assay for the Detection of Botulinum Neurotoxin in Animal Sera.

Authors:  Lmar Babrak; Alice Lin; Larry H Stanker; Jeffery McGarvey; Robert Hnasko
Journal:  Toxins (Basel)       Date:  2016-01-04       Impact factor: 4.546

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.